Active metronomic vinorelbine schedules decrease plasma interleukin-2 levels in mice with Lewis lung carcinoma

References

• Shaked Y, Emmenegger U, Man S, Cervi D, Bertolini F, Ben-David Y, Kerbel RS. Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood. 2005; 106(9):3058–61.
   PubMed Web of Science ®Google Scholar
• Mavroeidis L, Sheldon H, Briasoulis E, Marselos M, Pappas P, Harris AL. Metronomic vinorelbine: Anti-angiogenic activity in vitro in normoxic and severe hypoxic conditions, and severe hypoxia-induced resistance to its anti-proliferative effect with reversal by Akt inhibition. Int J Oncol. 2015; 47(2):455–64.
   PubMed Web of Science ®Google Scholar
• Bocci G, Kerbel RS. Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect. Nat Rev Clin Oncol. 2016;13(11):659–73.
   PubMed Web of Science ®Google Scholar
• Natale G, Bocci G. Does metronomic chemotherapy induce tumor angiogenic dormancy? A review of available preclinical and clinical data. Cancer Lett. 2018;432:28–37.
   PubMed Web of Science ®Google Scholar
• Di Desidero T, Derosa L, Galli L, Orlandi P, Fontana A, Fioravanti A, Marconcini R, Giorgi M, Campi B, Saba A, et al. Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients. Invest New Drugs. 2016;34(6):760–70.
   PubMed Web of Science ®Google Scholar
• Cox MC, Pelliccia S, Marcheselli L, Battistini R, Arcari A, Borza PA, Patti C, Casaroli I, di Landro F, Di Napoli A, et al. The metronomic all-oral DEVEC is an effective schedule in elderly patients with diffuse large b-cell lymphoma. Invest New Drugs. 2019;37(3):548–58.
   PubMed Web of Science ®Google Scholar
• Cazzaniga ME, Munzone E, Bocci G, Afonso N, Gomez P, Langkjer S, Petru E, Pivot X, Sánchez Rovira P, Wysocki P, et al. Pan-European expert meeting on the use of metronomic chemotherapy in advanced breast cancer patients: the PENELOPE Project. Adv Ther. 2019;36(2):381–406.
   PubMed Web of Science ®Google Scholar
• Pujol J-L, Coffy A, Camerini A, Kotsakis A, Mencoboni M, Gusella M, Pasini F, Pezzuto A, Banna GL, Bilir C, et al. An individual patient-data meta-analysis of metronomic oral vinorelbine in metastatic non-small cell lung cancer. PLoS One. 2019;14(8):e0220988
   PubMed Web of Science ®Google Scholar
• Camerini A, Puccetti C, Donati S, Valsuani C, Petrella MC, Tartarelli G, Puccinelli P, Amoroso D. Metronomic oral vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer: results of a phase II trial (MOVE trial). BMC Cancer. 2015;15:359
   PubMed Web of Science ®Google Scholar
• Mencoboni M, Filiberti RA, Taveggia P, Del Corso L, Del Conte A, Covesnon MG, Puccetti C, Donati S, Auriati L, Amoroso D, et al. Safety of first-line chemotherapy with metronomic single-agent oral vinorelbine in elderly patients with NSCLC. Anticancer Res. 2017; Jun37(6):3189–94.
   PubMed Web of Science ®Google Scholar
• Orlandi P, Di Desidero T, Salvia G, Muscatello B, Francia G, Bocci G. Metronomic vinorelbine is directly active on Non Small Cell Lung Cancer cells and sensitizes the EGFRL858R/T790M cells to reversible EGFR tyrosine kinase inhibitors. Biochem Pharmacol. 2018;152:327–37.
   PubMed Web of Science ®Google Scholar
• Abbas AK, Trotta E, D RS, Marson A, Bluestone JA. Revisiting IL-2: biology and therapeutic prospects. Sci Immunol. 2018;3(25):eaat1482.
   PubMed Web of Science ®Google Scholar
• David JM, Dominguez C, Hamilton DH, Palena C. The IL-8/IL-8R axis: a double agent in tumor immune resistance. Vaccines. 2016;4(3):22.
   PubMed Web of Science ®Google Scholar
• Bocci G, Falcone A, Fioravanti A, Orlandi P, Di Paolo A, Fanelli G, Viacava P, Naccarato AG, Kerbel RS, Danesi R, et al. Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib. Br J Cancer. 2008;98(10):1619–29.
   PubMed Web of Science ®Google Scholar
• Di Desidero T, Orlandi P, Fioravanti A, Alì G, Cremolini C, Loupakis F, Gentile D, Banchi M, Cucchiara F, Antoniotti C, et al. Chemotherapeutic and antiangiogenic drugs beyond tumor progression in colon cancer: Evaluation of the effects of switched schedules and related pharmacodynamics. Biochem Pharmacol. 2019;164:94–105.
   PubMed Web of Science ®Google Scholar
• Xu K, Liu T, Zhang J, Zhou Y, Yang F, Ren T. The efficacy and toxicity of metronomic oral vinorelbine monotherapy in patients with non-small cell lung cancer: a meta-analysis. Int J Clin Oncol. 2020;25(9):1624–34. May 29;
   PubMed Web of Science ®Google Scholar
• Garcia-Sanz M, Simon-Marin R, Hilario E. Morphological characterization of Lewis lung carcinoma (3LL). A Light Electron Microscopic Study. Tumori. 1989; Feb 2875(1):23–7.
   Google Scholar
• Qin R-S, Zhang Z-H, Zhu N-P, Chen F, Guo Q, Hu H-W, Fu S-Z, Liu S-S, Chen Y, Fan J, et al. Enhanced antitumor and anti-angiogenic effects of metronomic Vinorelbine combined with Endostar on Lewis lung carcinoma. BMC Cancer. 2018; Oct 1118(1):967
   PubMed Web of Science ®Google Scholar
• Ohue Y, Nishikawa H. Regulatory T (Treg) cells in cancer: can Treg cells be a new therapeutic target?. Cancer Sci. 2019; Jul110(7):2080–9.
   PubMed Web of Science ®Google Scholar
• Wu J, Waxman DJ. Metronomic cyclophosphamide eradicates large implanted GL261 gliomas by activating antitumor Cd8+ T-cell responses and immune memory . Oncoimmunology. 2015;4(4):e1005521
   PubMed Web of Science ®Google Scholar
• Ge Y, Domschke C, Stoiber N, Schott S, Heil J, Rom J, Blumenstein M, Thum J, Sohn C, Schneeweiss A, et al. Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome. Cancer Immunol Immunother. 2012; Mar61(3):353–62.
   PubMed Web of Science ®Google Scholar
• Orecchioni S, Talarico G, Labanca V, Calleri A, Mancuso P, Bertolini F. Vinorelbine, cyclophosphamide and 5-FU effects on the circulating and intratumoural landscape of immune cells improve anti-PD-L1 efficacy in preclinical models of breast cancer and lymphoma. Br J Cancer. 2018;118(10):1329–36.
   PubMed Web of Science ®Google Scholar
• Fong A, Durkin A, Lee H. The potential of combining tubulin-targeting anticancer therapeutics and immune therapy. IJMS. 2019;20(3):586.
   Google Scholar